Age accelerates the progression from HIV-seroconversion to AIDS in women. Italian Seroconversion Study (HIV-ISS). NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Age accelerates the progression from HIV-seroconversion to AIDS in women. Italian Seroconversion Study (HIV-ISS).

Int Conf AIDS. 1992 Jul 19-24;8(1):Mo10 (abstract no. MoC 0033). Unique Identifier : AIDSLINE ICA8/92399985
Rezz G; Pezzotti P; Dorrucci M; Angarano G; Castelli F; Sinicco A; Costigliola P; Canessa A; Pristera R; Zerboni R; et al


Abstract: OBJECTIVES: To estimate the risk of developing AIDS for women compared to that of men, and to identify predictors of clinical progression in women. METHODS: We conducted a longitudinal study, enrolling individuals for whom the seroconversion period could be estimated (i.e. availability of a negative serological test and a subsequent HIV-positive test within two years of the former date). The seroconversion date was estimated as the midpoint between the last negative and the first HIV-positive test. The end-point of the analysis was the AIDS diagnosis. Disease progression was analyzed according to estimates based on Kaplan-Meier survival curves. Differences among groups were assessed by the log-rank test. RESULTS: Two-hundred-thirty-four females (141 IDUS; 93 heterosexual contact) and 422 males (377 IDUS; 45 heterosexual contact) from 16 Italian clinical facilities were enrolled in the study. The mean age was 25.93 years (24.59 for females and 26.67 for males). The median seroconversion interval (the period between the last negative and first positive test) was 7.95 months (8.02 for females and 7.06 for males). The median follow-up time was 43.97 months (38.23 females; 45.23 males). Seven women and 31 men developed AIDS during the study period. The estimated cumulative incidence of AIDS was 3.49% (95% C.I. 0.24-6.74) for women and 6.08% (95% C.I. 3.30-8.86) for men within 4 years after seroconversion. No significant differences were found in the progression of HIV between women and men. Women over 25 years old at seroconversion were more likely to develop AIDS than those younger than 25. No differences were found in women between injecting drug users and heterosexual contacts. CONCLUSIONS: In industrialized countries, the natural history of HIV infection in women does not seem to differ from that of men. Factors such as older age at seroconversion may play a role in accelerating the progression from HIV infection to AIDS.
Keywords: Acquired Immunodeficiency Syndrome/*EPIDEMIOLOGY Adult Age Factors Comparative Study Female Human HIV Seropositivity/*EPIDEMIOLOGY/TRANSMISSION Italy/EPIDEMIOLOGY Prospective Studies Sex Behavior Substance Abuse, Intravenous/COMPLICATIONS/EPIDEMIOLOGY ABSTRACTKWDacquiredimmunodeficiencysyndrome/KWDepidemiologyadultagefactorscomparativestudyfemalehumanhivseropositivity/KWDepidemiology/transmissionitaly/epidemiologyprospectivestudiessexbehaviorsubstanceabuse,intravenous/complications/epidemiologyabstract
921230
M92C5362

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .